Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2009

View Archived Issues

Cylene Pharmaceuticals presents data on CK2 inhibitor CX-4945

Dual antibody Sym-004 shows anticancer promise in vitro and in vivo

Molecular mechanisms potentially involved in telaprevir-resistance in HCV treatment identified

Long-lasting efficacy seen with botulinum toxin type B in PD patients with sialorrhea

PF-04929113 well tolerated in ongoing first-in-man study in cancer patients

Novartis claims novel DGAT-1 inhibitors

Abbott describes novel antagonists of chemokine CCR2 receptors for rheumatoid arthritis

Neutrophil elastase inhibitors described by Argenta Discovery in recent patent

Progenics reports on HCV entry inhibitor PRO-206

Celsion enrolls first patient in ThermoDox phase I/II breast cancer trial

MK-3281 pharmacokinetics in healthy volunteers indicate twice-daily dosing

Presentations describe novel non-nucleoside HCV polymerase inhibitors ABT-072, ABT-333

Novel histamine H3 receptor antagonists for the treatment of AD presented by Wyeth

Takeda discloses Polo-like kinase inhibitors for the treatment of cancer

NanoViricides and PURE Bioscience report on measures to combat swine influenza

Chelsea Therapeutics reports results from phase I CH-4051 trial

Archimedes submits MAA to EMEA for NasalFent in cancer pain

Bayer and Ardea enter global MEK inhibitors agreement for cancer indications

Japanese government accelerates Hemispherx Biopharma's Ampligen vaccine program

UCB reports first results from phase III brivaracetam studies in epilepsy

SPA agreement for second phase III trial of OGX-011 in prostate cancer

Epigenomics and Predictive Biosciences sign prostate cancer biomarker deal

Bacilligen receives NIAID grant to develop influenza vaccine

TcLand Expression receives support for biomarker research in kidney rejection

Inimex's innate defense regulator IMX-942 begins clinical studies

FDA extends action date for inhaled treprostinil NDA by three months

Isotechnika's phase III ESSENCE data meets primary endpoint in psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...